Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
| 8.13 | |
| 8.02 | |
| - | |
| 8.19 | |
| 8 | |
| 7.44-11.71 | |
| 398 M | |
| 48 922 K | |
| 62 017 K | |
| -0.28 | |
| 0.247 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Theravance Biopharma, Inc. (NASDAQ:TBPH) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Theravance Biopharma, Inc., a biopharmaceutic...
A downtrend has been apparent in Theravance Biopharma (TBPH) lately with too much selling pressure. The stock has declined 11.2% over the past four weeks. However, given the fact that it is now in ove...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
